Primecap Management Co. CA Trims Stake in Mural Oncology plc (NASDAQ:MURA)

Primecap Management Co. CA lessened its holdings in shares of Mural Oncology plc (NASDAQ:MURA) by 40.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 140,045 shares of the company’s stock after selling 95,506 shares during the quarter. Primecap Management Co. CA’s holdings in Mural Oncology were worth $438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. Harbor Capital Advisors Inc. bought a new position in Mural Oncology in the 2nd quarter worth $115,000. Rhumbline Advisers bought a new position in shares of Mural Oncology in the second quarter worth about $34,000. BBR Partners LLC bought a new position in shares of Mural Oncology in the second quarter worth about $31,000. Acadian Asset Management LLC purchased a new position in shares of Mural Oncology during the 2nd quarter valued at about $998,000. Finally, Nicollet Investment Management Inc. bought a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $308,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Insider Activity

In related news, CFO Adam D. Cutler sold 7,421 shares of the firm’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the transaction, the chief financial officer now directly owns 71,438 shares of the company’s stock, valued at approximately $243,603.58. This trade represents a 9.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on MURA shares. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a research note on Monday, November 11th. Raymond James initiated coverage on Mural Oncology in a research note on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target for the company.

Mural Oncology Stock Performance

Shares of NASDAQ:MURA opened at $3.35 on Friday. The firm has a market cap of $57.02 million and a price-to-earnings ratio of -0.36. The firm has a fifty day moving average price of $3.41 and a 200 day moving average price of $3.37. Mural Oncology plc has a fifty-two week low of $2.88 and a fifty-two week high of $6.25.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.